Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02147990
Title TIGER-2: A Phase 2, Open-label, Multicenter, Safety and Efficacy Study of Oral CO-1686 as 2nd Line EGFR-directed TKI in Patients With Mutant EGFR Non-small Cell Lung Cancer (NSCLC)
Acronym NSCLC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Clovis Oncology, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | GBR | FRA | ESP | DEU | CHE | CAN | AUS


No variant requirements are available.